Neurology
AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTAâ„¢ on Monday November 1, 2010
November 1, 2010 3:34 am | by Bio-Medicine.Org | News | CommentsALISO VIEJO, Calif., Nov. 1, 2010 /- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR ) today announced a management conference call to discuss the approval of NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) by the U.S. Food and Drug Administration (FDA). The call is...
Philips Introduces High Field Open MRI for Radiation Oncology
October 31, 2010 7:33 am | by Bio-Medicine.Org | News | CommentsANDOVER, Mass., Oct. 31 /- Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the Philips Panorama High Field Open (HFO) Oncology Configuration for radiation therapy, a magnetic resonance (MR) imaging solution for dedicated oncology use, at this year's American Society for...
VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuber...
October 30, 2010 6:35 pm | by Bio-Medicine.Org | News | CommentsNEW YORK, Oct. 30 /- See video from Novartis at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=193bd015... Novartis announced that the US Food and Drug Administration (FDA) has approved Afinitor®; (everolimus) tablets for patients with...
Zebrafish yield clues to how we process visual information
October 29, 2010 1:35 pm | by Lawrence Berkeley National Laboratory | News | CommentsTo a hungry fish on the prowl, the split-second neural processing required to see and gobble up prey is a matter of survival. To scientists, it’s a window into how our brain coordinates eye motions that enable us make our way in a world full of danger and opportunity. This process is now...
Chronic Migraine Is Associated With Reduced Household Income and Greater Headache Impact
October 29, 2010 12:33 am | by Bio-Medicine.Org | News | CommentsCHICAGO, Oct. 29 /PRNewswire-USNewswire/ -- New data presented today at The 2010 European Headache and Migraine Trust International Congress (EHMTIC) shows that persons with chronic migraine (headache on greater than or equal to 15 days per month) are much more likely to have annual...
Technology, New Therapies Reduce Use of Addictive Prescriptions
October 28, 2010 11:34 am | by Bio-Medicine.Org | News | CommentsWEST PALM BEACH, Fla., Oct. 28 /- The truth is...not all pain is created equal. Acute pain is where it all begins. Lasting for several months, acute pain is typically treated with rest, time and medication. For many, that is enough. But if the pain persists, it...
Vanda Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 3, 2010
October 28, 2010 8:33 am | by Bio-Medicine.Org | News | CommentsROCKVILLE, Md., Oct. 28 /- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the third quarter of 2010, on...
CyberKnife Center of Miami Lends a Hand in Treatment of Haitian Nurse
October 28, 2010 6:33 am | by Bio-Medicine.Org | News | CommentsMIAMI, Oct. 28 /- Who would've guessed that among all the tragic injuries and infectious disease resulting from Haiti's earthquake that a brain tumor patient would be treated along the way? The CyberKnife Center of Miami is helping out by donating the treatment, care, lodging and expenses...
Boston Scientific Agrees to Sell Neurovascular Business to Stryker
October 28, 2010 4:32 am | by Boston Scientific | News | CommentsNATICK, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular
Adeona to Hold Annual Shareholder Meeting
October 28, 2010 2:33 am | by Bio-Medicine.Org | News | CommentsANN ARBOR, Mich., Oct. 28 /- Adeona Pharmaceuticals, Inc., (AMEX: AEN ) announced today that the Company will hold its Annual Shareholders Meeting on Tuesday, November 2, from 9 a.m. to 10 a.m., at its offices located at 3930 Varsity Drive, Ann Arbor, MI, 48108. During the Annual...
InVivo Therapeutics raises $10.5M, completes reverse merger
October 27, 2010 10:33 am | by Mass High Tech: The Journal of New England Technology | News | CommentsInVivo Therapeutics Corp., a Cambridge spinal cord injury treatment developer, has completed a reverse merger and initiated a $10.5 million private placement offering.
Neurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
October 26, 2010 12:33 pm | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Oct. 26 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Oppenheimer 21st Annual Healthcare Conference in New York. The live presentation takes...
Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
October 26, 2010 9:33 am | by Bio-Medicine.Org | News | CommentsHAMILTON, N.J. and ROCKVILLE, Md., Oct. 26 /- MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN ) a clinical stage pharmaceutical company developing and commercializing potential best in...
Siemens Wins $25 Million Contract From Rush University Medical Center
October 26, 2010 9:33 am | by Bio-Medicine.Org | News | CommentsMALVERN, Pa., Oct. 26 /- Rush University Medical Center in Chicago, one of the top academic medical centers in the United States, has awarded a five-year, $25 million contract for medical equipment and health IT consulting services to Siemens Medical Solutions USA, Inc. With the addition...
Gene Therapy for Treating Depression
October 25, 2010 8:33 pm | by Massachusetts Institute of Technology | News | CommentsResearchers find they can alleviate depression in mice by boosting a protein in one part of the brain.
FDA Issues Complete Response Letter for Lorcaserin New Drug Application
October 23, 2010 12:31 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 23, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is...
Collagen Matrix, Inc. Expands Operations and Moves Corporate Headquarters to Oakland, New Jersey
October 21, 2010 5:33 am | by Bio-Medicine.Org | News | CommentsOAKLAND, N.J., Oct. 21 /- Collagen Matrix, Inc., the leader in collagen- and mineral-based matrix engineering, announced today that it is expanding its operations by the addition of a 28,000 sq. ft. facility at 15 Thornton Road, Oakland, New Jersey 07436. The company will be relocating...
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
October 20, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Oct. 20 /- Pfizer Inc. (NYSE: PFE ) announced today that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines. Pfizer will acquire a 40 percent stake...
Patient dies in Biogen MS drug trial
October 19, 2010 11:32 am | by Mass High Tech: The Journal of New England Technology | News | CommentsIn a Phase 2 clinical trial, Biogen Idec and Roche reported their multiple sclerosis treatment, ocrelizumab, showed signs of reducing the disease indications – but they also reported that one patient died during the testing.
Where Should Companies Innovate? In Their Enterprises.
October 19, 2010 8:32 am | by Bio-Medicine.Org | News | CommentsCENTER VALLEY, Pa., Oct. 19 /- Olympus Corporation of the Americas ( www.olympusamerica.com ) today released findings from a Harris Interactive survey of Fortune 1000 executives concerning enterprise innovation – defined as the transformative business processes, practices,...
The Promise of Ion Beam Cancer Therapy
October 18, 2010 12:35 pm | by Lawrence Berkeley National Laboratory | News | CommentsThe world’s foremost experts in ion-beam cancer therapy meet at Oakland’s Claremont Hotel October 26 through 29 to examine the international success of this unique therapy, explore future developments, and ask tough questions – including why this extraordinary medical advance is making...
Experimental Drug Preserves Memory in Rodents
October 17, 2010 8:32 pm | by Massachusetts Institute of Technology | News | CommentsA new compound prevents age-related memory loss by blocking part of the stress system.
Galenea wins $4.5M NIH grant
October 17, 2010 4:32 am | by Mass High Tech: The Journal of New England Technology | News | CommentsCambridge biopharmaceutical firm Galenea Corp. has won a $4.5 million grant from the National Institute of Mental Health for a technology platform aimed at identifying compounds to treat schizophrenia.
Omeros to Present at the BioCentury NewsMakers Conference
October 15, 2010 5:32 am | by Bio-Medicine.Org | News | CommentsSEATTLE, Oct. 15 /- Omeros Corporation (Nasdaq: OMER ), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief...
Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
October 11, 2010 8:32 am | by Bio-Medicine.Org | News | CommentsRESEARCH TRIANGLE PARK, N.C., Oct. 11 /- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR ) will issue its third quarter 2010 earnings release before the market opens on October 28, 2010. Due to the pending merger with Grifols, S.A., Talecris will not be hosting a conference call to...
